Researchers
-
Alejandra Marín Arguedas
Pneumology
-
Alex Roger Reig
Pneumology
Phd -
Carme Santiveri Gilabert
Pneumology
-
Concepción Cañete Ramos
Pneumology
-
Elena Marcos
Pneumology
-
Elena Miguel Campos
Pneumology
-
Josefina Sabria
Pneumology
Phd -
Lydia Luque Chacon
Pneumology
-
Mª Victoria González
Pneumology
-
Rose Blavia Aloy
Pneumology
-
Rosa Montoliu Tarramera
Pneumology
Contact the group
Form
Projects
-
- Year 2019
- Sant Joan Despí Moisès Broggi Hospital
Infections by non-tuberculous mycobacteria (NTM) in Spain: Epidemiological, microbiological and pathogenic clinical study.
-
DISTRICT ATTORNEY:
Dr. Fernando Alcaide Fernández De Vega of the Microbiology Service of the Bellvitge University Hospital
-
TYPE E:
EPA-AS
-
- Year 2019
- Comprehensive Care Center Dos de Maig Hospital
Efficacy and safety of inhaled antibiotic therapy in patients with COPD and chronic bronchial infection.
-
DISTRICT ATTORNEY:
COPD and Bronchiectasis PII of the SEPAR (Spanish Society of Pulmonology and Thoracic Surgery)
-
TYPE E:
EPA-OD
-
Pneumology
Researcher
- Year 2018
- Sant Joan Despí Moisès Broggi Hospital
SPEAKER: Phase 3b, open, multicenter trial to evaluate the efficacy and safety of benralizumab 30 mg administered subcutaneously to reduce the use of oral corticosteroids in adult patients with severe eosinophilic asthma treated with high-dose inhaled corticosteroids plus a β2 agonist of prolonged action and chronic treatment with oral corticosteroids,
-
DISTRICT ATTORNEY:
AstraZeneca AB
-
TYPE E:
RD2015
-
Pneumology
Researcher
- Year 2018
- Sant Joan Despí Moisès Broggi Hospital
New diagnostic and therapeutic approaches in the control of infection and tuberculosis. INNOVA 4-TB,
-
DISTRICT ATTORNEY:
German Trias i Pujol Health Sciences Research Institute
-
TYPE E:
PI
-
Pneumology
Researcher
- Year 2018
- Sant Joan Despí Moisès Broggi Hospital
Observational, multinational and transversal study to describe the proportion and characteristics of patients with severe asthma eligible for referral to biological therapy in primary and specialized care settings in Europe,
-
DISTRICT ATTORNEY:
AstraZeneca PLC
-
TYPE E:
EPA
-
- Year 2018
- Sant Joan Despí Moisès Broggi Hospital
New diagnostic and therapeutic approaches in the control of infection and tuberculosis. INNOVA 4-TB,
-
DISTRICT ATTORNEY:
German Trias and Pujol Health Sciences Research Institute
-
TYPE E:
PINE TREE
-
- Year 2018
- Sant Joan Despí Moisès Broggi Hospital
Observational, multinational and transversal study to describe the proportion and characteristics of patients with severe asthma eligible for referral to biological therapy in primary and specialized care settings in Europe,
-
DISTRICT ATTORNEY:
AstraZeneca PLC
-
TYPE E:
EPA
-
- Year 2018
- Sant Joan Despí Moisès Broggi Hospital
SPEAKER: Phase 3b, open, multicenter trial to evaluate the efficacy and safety of benralizumab 30 mg administered subcutaneously to reduce the use of oral corticosteroids in adult patients with severe eosinophilic asthma treated with high-dose inhaled corticosteroids plus a β2 agonist of prolonged action and chronic treatment with oral corticosteroids,
-
DISTRICT ATTORNEY:
AstraZeneca AB
-
TYPE E:
RD2015
-
Pneumology
Researcher
- Year 2017
- Comprehensive Care Center Dos de Maig Hospital
Cross-sectional observational study to characterize severe COPD in Spain,
-
DISTRICT ATTORNEY:
Chiesi España SAU
-
TYPE E:
EPA
-
Pneumology
Researcher
- Year 2017
- Sant Joan Despí Moisès Broggi Hospital
Characterization of "homing" cellular receptors and study of the role of regulatory B cells in the diagnosis of tuberculosis,
-
DISTRICT ATTORNEY:
SEPAR (Spanish Society of Pulmonology and Thoracic Surgery)
-
TYPE E:
PI
Lines of action
- COPD: Cognitive impairment, quality of life and nutritional status
- bronchial asthma
- Obesity and lung function
- Obstruction of the upper airway secondary to goiter
- Hypersensitivity pneumonitis, interstitial lung disease
- Pulmonary tuberculosis and other communicable diseases of the respiratory system
